(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 June 2019 (13.06.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/113390 A1

(51) International Patent Classification:
A61K 38/19 (2006.01) *A61P 7/04* (2006.01)

(21) International Application Number:
PCT/US2018/064355

(22) International Filing Date:
06 December 2018 (06.12.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/596,020 07 December 2017 (07.12.2017) US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).

(72) Inventors: **TARANTINO, Michael**; 2 Old Farm Lane, Washington, IL 61571 (US). **BUSSEL, James**; 115 East 67th Street, #9B, New York City, NY 10065 (US). **EISEN, Melissa**; 969 Alexandra Court, Oak Park, CA 91377 (US). **CARPENTER, Nancy**; 44 Willow Drive, Carterton Oxfordshire OX18 1JU (GB). **WANG, Xuena**; 4516 Red Spruce Lane, Manlius, NY 13104 (US). **MAC, Susanna**; 30608 Rainbow View Drive, Agoura Hills, CA 91301 (US).

(74) Agent: **GAUL, Timothy, J.**; Amgen Inc., One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, CA 91320-1799 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

WO 2019/113390 A1

(54) **Title:** METHOD OF TREATING IDIOPATHIC THROMBOCYTOPENIA PURPURA (ITP) WITH ROMIPLOSTIM

(57) **Abstract:** The present invention concerns a method of treating idiopathic thrombocytopenia purpura (ITP) in a patient having ITP, which comprises: (a) administering romiplostim weekly to the patient; (b) increasing the weekly dose until a platelet count of at least about 50 to 200 x 10^9/L is reached; (c) decreasing the weekly dose of romiplostim if the platelet count remains $\geq$ 200 x 10^9/L for two consecutive weeks; (d) discontinuing romiplostim if the platelet count has remained $\geq$ 200 x 10^9/L for two consecutive weeks when the weekly dose is 1 µg/kg or the platelet count is $\geq$ 400 x 10^9/L; and (e) if a platelet count $\geq$ 200 x 10^9/L is reached within the first 4 to 12 weeks of treatment, maintaining a treatment-free period of at least about 24 weeks during which the patient receives no romiplostim.